Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Small Molecules
Filter     Order     Display # 
Date Item Title
05 Jun 2006 Results Of Phase II Studies Measure Progression Free Survival For Zactima (ZD6474) In Lung Cancer
05 Jun 2006 New Data Show That Five Years Of Treatment With Arimidex (Anastrozole) Did Not Cause Osteoporosis In Early Breast Cancer Patients With Normal Bone Mineral Density At Outset
05 Jun 2006 VELCADE® (Bortezomib) for Injection May Offer New Standard of Care in Relapsed/Refractory Mantle Cell Lymphoma
05 Jun 2006 VELCADE® (Bortezomib) for Injection Demonstrated High Single-Agent Response Rates in Newly Diagnosed Multiple Myeloma Patients
05 Jun 2006 Data from XYOTAX(TM) STELLAR Trials Presented at 2006 Meeting of American Society of Clinical Oncology
05 Jun 2006 Updated Analysis in Second-Line Treatment of Lung Cancer Trial Confirms Similar Survival for Alimta and Docetaxel
05 Jun 2006 Antisoma reports survival advantage for AS1404 in lung cancer and regains product rights
05 Jun 2006 Antisoma's AS1404 shows early promise in ovarian cancer trial
05 Jun 2006 Three Studies Confirm Activity of ABRAXANE As First-Line Treatment in Non-Small Cell Lung Cancer and Show Higher Tumor Response Rates Than Current Standard of Care
05 Jun 2006 Metabasis Therapeutics Presents Poster at American Society of Clinical Oncology
05 Jun 2006 New Data Show Enzastaurin's Activity Across Multiple Cancer Cell Lines
05 Jun 2006 Lilly Announces Phase II Results for ALIMTA(R) in First-Line Metastatic Breast Cancer Trial
04 Jun 2006 Pharmacyclics Additional Data and New Analyses From Pivotal Phase 3 SMART Trial Presented at ASCO 2006
04 Jun 2006 Data From a Randomized Phase II Study of Dasatinib or 800 Mg/Day Imatinib- Mesylate (Gleevec(R)) Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology
04 Jun 2006 Glivec® sets new treatment standard in chronic myeloid leukemia with high overall survival, increasing response and decreasing progression
04 Jun 2006 Cytogen Announces Positive Interim Findings from a Phase I Clinical Trial of QUADRAMET(R) Combination Study in Patients with Relapsed Multiple Myeloma
04 Jun 2006 Exelixis' XL880, the First Orally-Available MET Inhibitor in Clinical Development, Continues to Show Promise in a Phase I Trial in Patients With Advanced Solid Tumors
04 Jun 2006 Encouraging Phase I Trial Results for XL647 in Patients with Advanced Solid Malignancies Presented at ASCO
04 Jun 2006 GlaxoSmithKline reports positive new data on Tykerb (lapatinib ditosylate)
04 Jun 2006 Keryx Biopharmaceuticals, Inc. Announces Positive Data of KRX-0401 (Perifosine) in Patients With Advanced Renal Cell Carcinoma
03 Jun 2006 Bristol-Myers Squibb Issues Statement on Oncologic Drugs Advisory Committee Vote in Favor of Investigational Drug Dasatinib
03 Jun 2006 ZIOPHARM Announces Preliminary ZIO-101 Phase I Leukemia Data
03 Jun 2006 ASCO Publication Highlights Promising Data from ArQule's Phase I Combination Trial with ARQ 501 and Docetaxel
03 Jun 2006 FDA says tibolone not approvable as a menopause treatment in the U.S.
02 Jun 2006 Encysive Pharmaceuticals' Thelin(TM) (sitaxentan sodium) Receives Positive Opinion From European Authorities
02 Jun 2006 BioMarin and Alliant Announce FDA Approval of Orapred ODT
02 Jun 2006 Memory Pharmaceuticals Provides Update on MEM 3454 Program
02 Jun 2006 Threshold Announces Data Safety Monitoring Board Recommends Glufosfamide Phase 3 Clinical Trial Continue to Completion
02 Jun 2006 Rib-X Pharmaceuticals And Wakunaga Pharmaceutical Company Announce License Agreement For Quinolone Antibiotic
01 Jun 2006 Advancis Pharmaceutical Completes Enrollment in Amoxicillin PULSYS Phase III Trial
01 Jun 2006 Point Therapeutics Receives Fast Track Designation for Talabostat
01 Jun 2006 Cell Therapeutics, Inc. (CTI) and FDA Agree on NDA Filing Strategy for XYOTAX(TM)
01 Jun 2006 Update On Regulatory Filing Plans For Yondelis In Soft Tissue Sarcomas
01 Jun 2006 Javelin Enrolls First Patient In Pivotal Phase III Postop Pain Study of Dyloject(TM)
01 Jun 2006 Bioenvision Receives European Approval for Evoltra(TM); Orphan Drug Designation Gives Evoltra(TM) 10 Years Market Exclusivity in Europe
31 May 2006 Icagen Initiates Pediatric Clinical Development of ICA-17043 for Sickle Cell Disease
31 May 2006 Cardiome Announces Refusal to File Decision by the FDA
31 May 2006 Adolor's Complete Response to Approvable Letter for Entereg(R) (Alvimopan) in POI Accepted for Review by FDA
31 May 2006 Inspire Announces Plans to Begin Phase 2 Testing of Intranasal Epinastine for Seasonal Allergic Rhinitis; Pre-Investigational New Drug Meeting Completed With FDA
31 May 2006 Lilly Launches Phase III Trial of Once-Daily, Targeted Oral Cancer Agent
31 May 2006 Oral Compound BG-12 Achieves Primary Endpoint In Phase II Study Of Relapsing-Remitting Multiple Sclerosis
30 May 2006 Samaritan Reports Positive Preliminary Results with ''Oral'' HIV Entry Inhibitor in Phase II 10-Day HIV Monotherapy Trial
30 May 2006 Novelos Therapeutics Finalizes SPA with FDA for Phase 3 Trial in Lung Cancer
30 May 2006 Tramiprosate (Alzhemed™) preclinical results published in Neurobiology of Aging
30 May 2006 Phase II Clinical Trial of NeoPharm's LE-SN38 Initiated by NCI CALGB in Patients with Metastatic Colorectal Cancer; First Patients Treated
30 May 2006 ISTA Pharmaceuticals Is Initiating Phase III Clinical Trials of a New Once-Daily Formulation of Xibrom(TM) for the Treatment of Ocular Pain and Inflammation Following Cataract Surgery
30 May 2006 Localized delivery of PDE-4 inhibitors to open the therapeutic window
26 May 2006 Antipodean Pharmaceuticals Initiates Phase 2 Trial in Parkinson's Disease
26 May 2006 Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care In Management of Community-Treated Patients with Schizophrenia
26 May 2006 Sepracor Announces Presentation of LUNESTA(TM) Data at American Psychiatric Association Annual Meeting
 
<< Start < Prev 91 92 93 94 95 96 97 98 99 100 Next > End >>
Results 4951 - 5000 of 5705

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics